Nontyphoid Salmonella Infection: Microbiology, Clinical Features, and Antimicrobial Therapy  by Chen, Hung-Ming et al.
Pediatrics and Neonatology (2013) 54, 147e152Available online at www.sciencedirect.com
journal homepage: http: / /www.pediatr -neonatol .comREVIEW ARTICLE
Nontyphoid Salmonella Infection: Microbiology,
Clinical Features, and Antimicrobial TherapyHung-Ming Chen a,y, Yue Wang b,y, Lin-Hui Su c,*, Cheng-Hsun Chiu daDepartment of Pediatrics, Chang Gung Memorial Hospital, Chang Gung University of Science and Technology, Chiayi,
Taiwan
bWomen’s Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, PR China
cDepartment of Laboratory Medicine, Chang Gung Memorial Hospital, Chang Gung University, College of Medicine,
Taoyuan, Taiwan
dDepartment of Pediatrics, Chang Gung Children’s Hospital, Chang Gung University, College of Medicine, Taoyuan, Taiwan
Received Jul 31, 2012; received in revised form Oct 13, 2012; accepted Jan 22, 2013Key Words
antimicrobial
resistance;
antimicrobial
therapy;
Salmonella infection* Corresponding author. Department
Taiwan.
E-mail address: sulh@adm.cgmh.o
y Hung-Ming Chen and Yue Wang con
1875-9572/$36 Copyright ª 2013, Taiw
http://dx.doi.org/10.1016/j.pedneo.2Nontyphoid Salmonella is the most common bacterial pathogen causing gastrointestinal
infection worldwide. Most nontyphoid Salmonella infection is limited to uncomplicated gastro-
enteritis that seldom requires antimicrobial treatment. Nevertheless, invasive infections, such
as bacteremia, osteomyelitis, and meningitis, may occur and require antimicrobial therapy.
Continuous genetic and genomic evolution in Salmonella leading to increased virulence and re-
sistance to multiple drugs are of significant public health concern. Two major changes in the
epidemiology of nontyphoid salmonellosis in Europe and in the USA occurred in the second half
of the 20th century: the emergence of foodborne human infections caused by Salmonella en-
terica serotype Enteriditis and by multidrug-resistant strains of Salmonella enterica serotype
Typhimurium. In the 21st century, a worsening situation is the increasing resistance to fluoro-
quinolones and third-generation cephalosporins in nontyphoid Salmonella. Clinical isolates
showing carbapenem resistance also have been identified. Although antimicrobial therapy is
usually not indicated for uncomplicated Salmonella gastroenteritis, recent studies indicated
that a short-course ceftriaxone therapy (3e5 days) for patients with severe gastroenteritis
would lead to a faster clinical recovery. Continuous surveillance of Salmonella in both humans
and animals is mandatory. A better understanding of the mechanisms that lead to the emer-
gence of antimicrobial resistance in Salmonella may help in the devising of betterof Laboratory Medicine, Chang Gung Memorial Hospital, 5 Fu-Hsin Street, Kweishan, Taoyuan 333,
rg (L.-H. Su).
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Salmonella serogroup/serotype
D/Typhi
A,B,C/Paratyphi
B/Typhimurium
D/Enteritidis
D/Dublin
B/Derby
D/Gallinarum
B/Abortusovis
B/Abortusequi
C/Choleraesuisinterventional strategies to reduce the spread of resistant Salmonella between humans and
reservoirs along the food chain.
Copyright ª 2013, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Salmonella are important pathogens in humans and ani-
mals. There are approximately 1.4 million salmonellosis
cases each year in North America, with at least 22% of cases
requiring hospitalization for medical treatment.1 Over the
last decade, there has been a 25% reduction in the inci-
dence of foodborne illness caused by pathogens such as
Escherichia coli O157 and Campylobacter but only negli-
gible reductions in salmonellosis.2 A recent report also
indicated that the global burden of nontyphoid Salmonella
gastroenteritis remains high at 93.8 million cases, with
155,000 deaths and an average incidence of 1.14 episodes/
100 person-years each year.3 The figures are extraordinarily
highest in Asia, with 83.4 million cases, 137.7 thousand
deaths, and an average incidence of 4.72/100 person-years
each year.3
Salmonella has been recognized as a cause of intestinal
diseases for many years. Control of Salmonella infection is
difficult due to the bacterium’s high tolerance to environ-
mental stress, widespread distribution, multiple drug
resistance, and adaptability. The present report aims to
provide an overview of the organism, including micro-
biological and clinical features, current situations of anti-
microbial resistance and therapy.2. Taxonomy
The genus Salmonella comprises three species, Salmonella
enterica, Salmonella bongori, and Salmonella subterra-
nean.4 The type species, S. enterica, is further classified
into six subspecies: enterica (subsp. I), arizonae (subsp.
IIIa), diarizonae (subsp. IIIb), houtenae (subsp. IV), indica
(subsp. VI), and salamae (subsp. II).4 Salmonella strainsease spectrum of representativ
Host
Humans
Humans
Humans, cattle, sw
sheep, poultry, wil
Humans, poultry, w
Cattle, swine, shee
Birds, swine
Poultry
Sheep
Horses
Swinebelong to over 50 serogroups based on the O antigen, and to
over 2500 serotypes (each having a unique combination of
somatic O, and flagellar H1 and H2 antigens). Most of these
serotypes belong to one single Salmonella subspecies,
enterica, and are associated with >99% of Salmonella-
caused diseases in humans, including gastroenteritis and
enteric fever.5
Genome sequencing and comparative genomic analysis
revealed a close similarity of core regions from various
Salmonella genomes, together with evidence of recombi-
nation and rearrangement, genomic degradation, pseudo-
genes, and clonal diversity both within and among the
serotypes.6,7 Genomic comparisons of host-restricted
(S. Typhi, S. Paratyphi, and S. Gallinarum) and host-
adapted (S. Typhimurium and S. Enteridis) S. enterica se-
rotypes indicated that genomic degradation is a common
evolutionary mechanism for host adaptation and increased
pathogenicity of Salmonella.6,7 As described in the follow-
ing sections, continuous genetic re-assortment in Salmo-
nella, leading to increased virulence and the emergence of
resistance to multiple drugs, is of significant public health
concern.
3. Host Specificity
The degree of host adaptations varies among Salmonella
serotypes and affects the pathogenicity for man and ani-
mals (Table 1).8 Serotypes adapted to man, such as S. Typhi
and S. Paratyphi, usually cause severe septic typhoid syn-
drome (enteric fever) in humans. These serotypes are not
usually pathogenic to animals.
Serotypes that are highly adapted to animal hosts, such
as S. Gallinarum (poultry) or S. Abortusovis (sheep), may
only produce very mild symptoms in humans. However,
S. Choleraesuis, which swine is the primary host, alsoe Salmonella serotypes.8
Disease
Septicemia, fever
Septicemia, fever
ine, horses,
d rodents
Gastroenteritis, septicemia, fever
ild rodents Gastroenteritis, septicemia, fever
p Gastroenteritis, septicemia,
abortion, fever
Gastroenteritis, septicemia
Gastroenteritis, septicemia
Septicemia, abortion
Septicemia, abortion
Septicemia, fever
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S. Dublin, which has a preference for cattle as the host, is
primarily responsible for the systemic form of salmonellosis
in humans. This disease causes high mortality in young
calves and results in fever, reduced milk yield, diarrhea,
abortion, and occasionally death in mature cattle. Ubiqui-
tous serotypes, such as S. Enteritidis or S. Typhimurium,
which affect both man and animals, generally cause gas-
trointestinal infections with less severity than enteric
fever. However, they also have the capacity to produce
typhoid-like infections in mice and humans or asympto-
matic intestinal colonization in chickens.44. Salmonella Infection
The most common mode of Salmonella infection is acute
gastroenteritis. The incubation period may vary from 4
hours to 72 hours after the ingestion of contaminated food
or water. Symptoms are acute onset of fever and chills,
nausea and vomiting, abdominal cramping, and diarrhea. If
a fever is present, it generally subsides in 72 hours. Diar-
rhea is usually self-limiting, lasting 3e7 days, and may be
grossly bloody. Salmonella is excreted in feces after
infection, a process that may last for a median of 5 weeks.
In young children, the excretion may be prolonged. In older
children and adults, Salmonella excretion lasting >8 weeks
after infection is uncommon. Bacteremia occurs in 5e10%
of infected persons, and some of them may progress to
have focal infection, such as meningitis, and bone and joint
infection. Immunocompromised patients, especially those
who have impaired cellular immunity, may have prolonged
or recurrent Salmonella infection.9
Although nontyphoid Salmonella-associated blood-
stream or focal infection is relatively infrequent in most
developed and developing countries,10 the organisms are
among the most common bacteria causing bloodstreamFigure 1 Distribution of Salmonella cases among various age gro
Chang Gung Memorial Hospital during 2001e2011.infection, particularly in susceptible children and HIV-
infected adults, in some less developed countries.11 A
recent systematic review and meta-analysis indicated
a high prevalence (19%) of invasive nontyphoid Salmonella
infection among the community-acquired bloodstream in-
fections in Africa.12 Even with proper microbiological ex-
amination as well as appropriate antimicrobial therapy,
invasive nontyphoid Salmonella infection was reported to
be associated with a high mortality of 22e47% in African
adults and children.13,14
The number of bacteria that must be ingested to cause
symptomatic disease in healthy adults is 106e108 nontyphoid
Salmonella organisms. In infants and persons with certain
underlying conditions, a smaller inoculum can produce dis-
eases, so that direct person-to-person transmission, although
uncommon, sometimes occurs. This is why nontyphoid Sal-
monella infection tends to occur in children, especially in
children aged <2 years.15
Figure 1 demonstrates the distribution of Salmonella
cases among various age groups of patients treated in
Chang Gung Children’s Hospital and Chang Gung Memorial
Hospital during 2001e2011. Among the total of 8163 cases,
62% were children younger than 5 years. The incidence
increased rapidly right after birth. At the second year of
life, the case numbers of serogroups C and D infection
continued to grow, but that of serogroup B infection
became flattened. Infection caused by all Salmonella
serogroups decreased very rapidly among children after age
3 years and remained at a low level throughout the adult
ages.
Similar to a previous report,15 the changing trend of
Salmonella cases among different age groups of patients
was generally the same for various serogroups, but children
younger than 5 years were more likely to have serogroup B
infection than older children (p < 0.0001, Chi-square test).
Furthermore, although serogroup B has caused the largest
proportion of nontyphoid Salmonella infections, theups of patients treated in Chang Gung Children’s Hospital and
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exceeded that of serogroup B for patients older than 5
years (Figure 1).5. Antimicrobial Resistance
An inevitable side effect of antibiotic use, which is asso-
ciated with the adaptability of bacteria and microbial
genome evolution, is the emergence and dissemination of
resistant bacteria, not only in pathogenic bacteria but also
in the endogenous flora of man and animals. Resistant
commensal bacteria of food animals, such as zoonotic
bacteria, might contaminate meat products, thus reaching
the intestinal tract of humans.9 Resistance genes against
antibiotics that are or have only been used in animals were
soon after their introduction found not only in animal
bacteria, but also in the commensal flora of humans, in
zoonotic pathogens such as Salmonella, and in strictly
human pathogens, such as Shigella. There is evidence that
resistance determinants can transfer between unrelated
bacteria, such as Bacteroides, on the one hand, and Sal-
monella and Escherichia on the other.16 Therefore, not only
may the clonal spread of resistant strains occur, but there is
also a transfer of resistance genes between human and
animal bacteria.16
Antimicrobial resistance in nontyphoid Salmonella se-
rotypes is a global problem. Surveillance data demonstrate
an obvious increase in overall antimicrobial resistance
among salmonellae from 20e30% in the early 1990s to as
high as 70% in some countries at the turn of the century.5
The resistance rate, however, varies with different sero-
types and different antibiotics.17e19 S. Enteritidis, one of
the most prevalent Salmonella serotypes, is relatively more
susceptible to antimicrobial agents than are other
serotypes.5 A much higher rate of resistance was found in
S. Typhimurium, another globally prevalent serotype.
Multidrug-resistant S. Typhimurium definitive phage type
(DT) 104 emerged during the last 2 decades as a global
health problem because of its involvement in diseases
among both animals and humans.20 Multidrug-resistant
strains of this phage type were first detected in the UK in
cattle and humans in the late 1980s but have since become
common in other animal species such as poultry, pigs, and
sheep.21 Human infections with multidrug-resistant DT104
isolates have been associated with the consumption of
chicken, beef, pork, sausages, and meat paste. The
S. Typhimurium DT104 epidemic is now worldwide, with
a considerable number of outbreaks since 1996 in the USA
and Canada. These multidrug-resistant strains are generally
resistant to ampicillin, chloramphenicol/florfenicol, strep-
tomycin/spectinomycin, sulfonamides, and tetracyclines.20
Genes associated with these resistance properties have
been found to be chromosomally encoded. Multidrug
resistance in S. Typhimurium DT104 is mainly due to Sal-
monella genomic island 1 (SGI1), an integrative mobile
element, carrying various antibiotic resistance gene clus-
ters, and to conjugative R plasmids that confer resistance
to many antibiotics including extended-spectrum cephalo-
sporins.22,23 Additional resistance to trimethoprim, occa-
sionally seen among S. Typhimurium DT104 strains, may be
encoded by a nonconjugative but mobilizable plasmid(approximately 40 kb in length) which also encodes resist-
ance to sulfonamides.24
The increasing rates of resistance to traditional
agents (i.e., ampicillin, chloramphenicol, and trimetho-
primesulfamethoxazole) have turned the treatment of
invasive salmonellosis into a clinical dilemma. The emer-
gence of resistance to fluoroquinolones among nontyphoid
Salmonella is of particular concern, since this class of
antimicrobial agents constitutes the drug of choice for
treating potentially life-threatening Salmonella infections
caused by multiple-antibiotic resistant strains in adults.25
All fluoroquinolones have the same mechanisms of action
regardless of whether they are in clinical or veterinary
medicine. These antibiotics inhibit the topoisomerase
genes, leading to inhibition of DNA replication. This com-
mon mechanism of action means that resistance to one
fluoroquinolone will confer resistance to all other fluo-
roquinolones.26 In Salmonella, quinolone resistance was
initially attributed to point mutations in the gyrA gene
encoding the A subunit of gyrase, whose complex with DNA
is the primary target of quinolones. Resistance mutations of
gyrA occur in a region of the gene product between amino
acids 67 and 106, termed the quinolone resistance-
determining region (QRDR). Amino acid changes at Ser-83
(to Phe, Tyr, or Ala) or at Asp-87 (to Gly, Asn, or Tyr) are
the most frequently observed in nalidixic acid (Nal)-resist-
ant strains.27 Fluoroquinolone-resistant isolates can also
have an altered gyrB gene encoding the B subunit of
gyrase.28 This consists of a single mutation in the QRDR of
gyrB leading to amino acid change Ser464Phe.29
Fluoroquinolone-resistant isolates can also carry a fourth
mutation in the QRDR of parC encoding the ParC subunit of
topoisomerase IV, which is the secondary target for quino-
lones.26,27 The mutation identified led to amino acid change
Ser80Ile.30
Another worrisome situation is the emergence of cef-
triaxone resistance in nontyphoid Salmonella, which is
a big problem in Asian countries, including Taiwan.17,31
Ceftriaxone resistance of nontyphoid Salmonella is usu-
ally attributed to the presence of a plasmid-mediated
b-lactamase gene, blaCMY-2, which is usually located on
a transposon-like DNA element bearing a specific ISEcp1-
blaCMY-2-blc-sugE structure.
7,31 This conserved DNA frag-
ment, subsequently named Tn6092,32 has been reported
from different geographic areas and is being widely dis-
tributed among various Salmonella serotypes and other
members of the family Enterobacteriaceae.33 It was
recently found that the Tn6092 is carried by a conjugative
IncI1 plasmid and may have already spread widely among
other serotypes of nontyphoid Salmonella, particularly
among S. Typhimurium.31
For patients with invasive Salmonella infections that are
resistant to both ciprofloxacin and ceftriaxone, carbape-
nems may be the last drug of choice.34 However, in 2010,
a carbapenem-resistant S. Typhimurium was identified from
a patient with urinary tract infections.35 The ceftriaxone-
resistant strain found in this patient initially carried
a blaCMY-2-containing Tn6092 on a conjugative IncI1 plas-
mid. In addition to its original OmpD deficiency, the strain
further developed OmpC deficiency during ertapenem
therapy, and hence became resistant to carbapenems.35
The emergence and dissemination of multidrug resistance
Nontyphoid Salmonella infection 151in nontyphoid Salmonella poses a serious threat to the
public health and warrants continuous surveillance.
6. Antimicrobial Therapy
Antimicrobial therapy is usually not indicated for nontoxic
immunocompetent patients. Acute gastroenteritis caused
by nontyphoid Salmonella is a self-limiting disease, and
treatment should consist mainly of fluid replacement. A
meta-analysis demonstrated that there is no evidence of any
clinical benefit of antibiotic therapy in otherwise healthy
children and adults with nonsevere Salmonella gastro-
enteritis.36 However, while the risk of developing bacter-
emia is low (<5% of all patients), certain patients, such as
young infants <3 months old, patients with toxic appear-
ance and suspected extraintestinal infection, immunocom-
promised patients, and patients with severe colitis, would
benefit from empirical antibiotic treatment.37
If bacteremia or an extraintestinal focal infection is
confirmed, the choice of the antibiotics would depend
on the susceptibility pattern of the strain and the
clinical condition. Options may include ampicillin,
trimethoprimesulfamethoxazole, fluoroquinolones or third-
generation cephalosporins, such as ceftriaxone, depending
on the results of in vitro susceptibility testing. A recent
study by Tsai et al showed that complications occurred in
7.9% of pediatric patients with Salmonella gastroenteritis,
with bacteremia being the most common.38 Patients with
high C-reactive protein (100 mg/L) were more frequently
put on empirical antimicrobial therapy and had more
complications than those without.38 Interestingly, these
patients usually became afebrile within 2e3 days after
initiation of adequate antimicrobial treatment.38 It is con-
cluded that a short course of ceftriaxone therapy (3e5
days) for such patients would lead to a faster clinical re-
covery.38 However, antibiotics should be discontinued as
soon as possible when the patient’s clinical condition im-
proves. Although fluoroquinolones are not recommended in
children, they may be used in serious infections if there is
no other alternative treatment available.
7. Conclusions
Salmonella is an important source of foodborne infection.
The majority of patients are children younger than 5 years.
Laboratory findings and clinical observation both suggest
that the organism is very adaptive to antimicrobial selec-
tion pressure.39 Continuous surveillance of Salmonella in
both humans and animals is mandatory for a better control
of the infections caused by the organism.
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